Category: White Papers

The 2021 Orphan Drug Commercialization Report describes the current state of play in orphan drug commercialization.

Today, life sciences commercial teams must process, organize and analyze more data than ever before. Traditionally, data warehouses were the linchpins of companies’ data management efforts. But the data warehouse of the past won’t cut it anymore. In this white paper, we describe how a life sciences company can build a robust enterprise data platform that drives commercial success.

Many life sciences companies find themselves drowning in a sea of technology that fails to deliver a meaningful return on investment. In this white paper, we describe how companies can create a technology ecosystem that enables and enhances the work of users across the commercial organization.

The best way to create a believable and defensible forecast is to build it using a flexible, lever-based forecast model. This kind of model will allow stakeholders to run scenarios quickly and understand the impact of the assumptions that make up the forecast. We explain the keys to creating a flexible, lever-based model.

Like a coach following last year’s game plan to prepare for this year’s championship, life sciences commercial operations leaders – especially those with previous roles at established pharmaceutical companies – may be tempted to deploy their last sales force design strategy on their next product launch. If that therapy is CAR T, commercial operations leaders need to create a whole new game plan. In this white paper we’ll discuss the keys to sales force design for CAR T therapies and describe how they differ from the strategy behind sales force design for traditional therapies.

To effectively promote orphan drugs, life sciences companies must get creative to follow rare disease patients’ winding journeys to diagnosis and treatment. We explore how companies can perform thorough investigations to more effectively match therapies up with patients.

Life sciences companies spend years researching, developing and testing therapies that offer exciting new possibilities for treatment. But it’s often the launch – that short time frame between R&D and product uptake – that determines whether the therapy will fly or flop. This white paper outlines how data-driven commercial operations help ensure long-term commercial success.

Pre-launch commercial decisions can set a pharmaceutical company up for sustained commercial success or generate negative consequences that can plague it for years to come.

Life sciences commercial leaders must capitalize on the wealth of data available today – as well as powerful advanced analytical techniques – to design segmentation and targeting plans that drive sales. At the same time, they must maximize sales rep acceptance of these plans. Read this white paper to learn how a life sciences company can create effective targeting plans that field sales representatives embrace.

The convergence of increasingly rich data and advanced analytical methods has propelled the use of machine learning forward in the life sciences industry. Machine learning can be especially beneficial when it comes to developing customer targeting plans. Read this white paper to learn how commercial leaders can use machine learning to enhance their targeting efforts.